Tilavonemab

DB17014InvestigationalProtein Based Therapies

Tilavonemab: Overview.

Mechanism: Pharmacologically active on Microtubule-associated protein tau
Curator reviewed
Also known as: Immunoglobulin g4, anti-(human tau protein) (human-mus musculus monoclonal pr-1649264 .gamma.4-chain), disulfide with human-mus musculus monoclonal pr-1649264 .kappa.-chain, dimer
Code names: ABBV-8E12 · C2N-8E12

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tilavonemab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.